Morphometry of the human substantia nigra in ageing and Parkinson’s disease

[1]  C. Finch.  Neuron atrophy during aging: programmed or sporadic? , 1993, Trends in Neurosciences.

[2]  I Litvan,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Journal of the Neurological Sciences.

[3]  H. Kimura,et al.  Retention of basic fibroblast growth factor immunoreactivity in dopaminergic neurons of the substantia nigra during normal aging in humans contrast with loss in Parkinson's disease , 1994, Brain Research.

[4]  D. Mash,et al.  Dopamine transporter‐immunoreactive neurons decrease with age in the human substantia nigra , 1999, The Journal of comparative neurology.

[5]  Hitoshi Takahashi,et al.  A newly discovered age-related synaptic change in the human locus ceruleus: morphometric and ultrastructural studies , 1996, Acta Neuropathologica.

[6]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[7]  H. Braak,et al.  Pattern of brain destruction in Parkinson's and Alzheimer's diseases , 2005, Journal of Neural Transmission.

[8]  H J Gundersen,et al.  The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[9]  K. Jellinger.  The morphological basis of mental dysfunction in Parkinson's disease , 2006, Journal of the Neurological Sciences.

[10]  E. Tolosa,et al.  Neuronal Changes in the Substantia Nigra with Aging: A Golgi Study , 1995, Journal of neuropathology and experimental neurology.

[11]  A. Rajput,et al.  Age, environments, and the number of substantia nigra neurons. , 1990, Advances in neurology.

[12]  C. Comella.  REM sleep disorders and parkinsonism , 2007, Journal of Neurology.

[13]  D. Dickson,et al.  Alpha-synuclein and the Lewy body disorders. , 2001, Current opinion in neurology.

[14]  John E. Duda,et al.  Olfactory Dysfunction in Parkinson’s Disease , 2007, Neurosignals.

[15]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[16]  H. Gundersen,et al.  Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator , 1991, The Anatomical record.

[17]  B. Pakkenberg,et al.  Histological changes of the dopaminergic nigrostriatal system in aging , 2004, Cell and Tissue Research.

[18]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[19]  J. Troncoso,et al.  Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease , 1994, The Lancet.

[20]  P. Mcgeer,et al.  Aging and extrapyramidal function. , 1977, Archives of neurology.

[21]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[22]  M. West,et al.  Total number of neurons in the layers of the human entorhinal cortex , 1998, Hippocampus.

[23]  D. Aarsland,et al.  Risk of dementia in Parkinson’s disease: A community-based, prospective study , 2001 .

[24]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[25]  Udo Rüb,et al.  Where Does Parkinson Disease Pathology Begin in the Brain? , 2002, Journal of neuropathology and experimental neurology.

[26]  R A Crowther,et al.  Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. , 1998, Neuroscience letters.

[27]  D. Mcilwain,et al.  The role of the cytoskeleton in cell body enlargement, increased nuclear eccentricity and chromatolysis in axotomized spinal motor neurons , 2005, BMC Neuroscience.

[28]  Y. Agid,et al.  Preservation of midbrain catecholaminergic neurons in very old human subjects. , 2000, Brain : a journal of neurology.

[29]  D. Dickson.  Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration , 1999, Journal of Neurology.

[30]  H. Gundersen,et al.  Unbiased stereological estimation of the number of neurons in the human hippocampus , 1990, The Journal of comparative neurology.

[31]  E. Cochran,et al.  Age‐related decreases in Nurr1 immunoreactivity in the human substantia nigra , 2002, The Journal of comparative neurology.

[32]  A. Swann,et al.  Prospective validation of Consensus criteria for the diagnosis of dementia with Lewy bodies , 2000, Neurology.

[33]  Ma,et al.  Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageing , 1999, Neuropathology and applied neurobiology.

[34]  P. V. Domburg,et al.  The Human Substantia Nigra and Ventral Tegmental Area: A Neuroanatomical Study With Notes on Aging and Aging Diseases , 1991 .

[35]  K. Jellinger,et al.  Alzheimer disease and cerebrovascular pathology: an update , 2002, Journal of Neural Transmission.

[36]  Mark J. West,et al.  Total numbers of neurons in the layers of the human entorhinal cortex. Hippocampus 1998;8:69–82 , 1998 .

[37]  H. Braak,et al.  α-Synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei , 2001, Acta Neuropathologica.

[38]  S. Resnick,et al.  Alpha-Synuclein Lesions in Normal Aging, Parkinson Disease, and Alzheimer Disease: Evidence from the Baltimore Longitudinal Study of Aging (BLSA) , 2005, Journal of neuropathology and experimental neurology.

[39]  K. Jellinger,et al.  The pathology of Parkinson's disease. , 2001, Advances in neurology.

[40]  R Brookmeyer,et al.  Age-specific incidence rates of Alzheimer’s disease , 2000, Neurology.

[41]  P. Yates,et al.  The effects of ageing on the pigmented nerve cells of the human locus caeruleus and substantia nigra , 1979, Acta Neuropathologica.

[42]  A. Lees,et al.  A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.

[43]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[44]  Michael J. Bannon,et al.  Age‐related and regional differences in dopamine transporter mRNA expression in human midbrain , 1997, Neurology.

[45]  B. Pakkenberg,et al.  Ageing of substantia nigra in humans: 
cell loss may be compensated by hypertrophy , 2002, Neuropathology and applied neurobiology.

[46]  H J Gundersen,et al.  The nucleator , 1988, Journal of microscopy.

[47]  P. Yates,et al.  Monoaminergic neurotransmitter systems in presenile Alzheimer's disease and in senile dementia of Alzheimer type. , 1984, Clinical neuropathology.

[48]  L. Forno,et al.  Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.

[49]  A. Hirano,et al.  A COMPARATIVE STUDY OF MODIFIED BIELSCHOWSKY, BODIAN AND THIOFLAVIN S STAINS ON ALZHEIMER'S NEUROFIBRILLARY TANGLES , 1986, Neuropathology and applied neurobiology.

[50]  S. Leff,et al.  Age‐related decreases in GTP‐cyclohydrolase‐I immunoreactive neurons in the monkey and human substantia nigra , 2000, The Journal of comparative neurology.

[51]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[52]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[53]  J. Morris,et al.  Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.